103D CONGRESS

1ST SESSION H. R. 1926

AN ACT

To amend the National Narcotics Leadership Act

and for other purposes.for the Office of National Drug Control Policy,of 1988 to extend and authorize appropriations
★

103D CONGRESS

1ST SESSION H. R. 1926

AN ACT

To amend the National Narcotics Leadership Act of 1988

to extend and authorize appropriations for the Office

of National Drug Control Policy, and for other purposes.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the ‘‘National Narcotics

5 Leadership Act Amendments of 1993’’.

6 SEC. 2. IMPLEMENTATION OF NATIONAL DRUG CONTROL

7 STRATEGY.

8 Section 1003(c) of the National Narcotics Leadership

9 Act of 1988 (21 U.S.C. 1502(c)) is amended—
2

•HR 1926 EH1S

1 (1) by redesignating paragraphs (5), (6), and

2 (7) as paragraphs (6), (7), and (8), respectively; and

3 (2) by inserting after paragraph (4) the follow4 ing:

5 ‘‘(5) The Director may require the inclusion, in the

6 budget submission to the Office of Management and

7 Budget by any National Drug Control Program agency,

8 of funding requests for specific initiatives that are consist9 ent with the President’s priorities for the National Drug

10 Control Strategy and certifications made pursuant to

11 paragraph (3).’’.

12 SEC. 3. REPORT ON REPROGRAMMING; OFFICE PERSON13 NEL RESTRICTION.

14 (a) REPORT ON REPROGRAMMING.—Section

15 1003(c)(7) of the National Narcotics Leadership Act of

16 1988, as redesignated by section 2(1) of this Act, is

17 amended to read as follows:

18 ‘‘(7) The Director shall report to the Congress on a

19 quarterly basis regarding the need for any reprogramming

20 or transfer of appropriated funds in an amount greater

21 than $5,000,000 for National Drug Control Program ac22 tivities.’’.

23 (b) OFFICE PERSONNEL RESTRICTION.—Section

24 1003 of the National Narcotics Leadership Act of 1988
3

•HR 1926 EH1S

1 (21 U.S.C. 1502) is amended by adding at the end the

2 following:

3 ‘‘(f) PROHIBITION ON POLITICAL CAMPAIGNING.—A

4 Federal officer in the Office of National Drug Control

5 Policy who is appointed by the President, by and with the

6 advice and consent of the Senate, may not participate in

7 Federal election campaign activities, except that such an

8 official is not prohibited by this subsection from making

9 contributions to individual candidates.’’.

10 SEC. 4. NATIONAL DRUG CONTROL STRATEGY OUTCOME

11 MEASURES.

12 Section 1005(a) of the National Narcotics Leadership

13 Act of 1988 (21 U.S.C. 1504(a)) is amended—

14 (1) in paragraph (2)(A) by inserting ‘‘and the

15 consequences of drug abuse’’ after ‘‘drug abuse’’;

16 and

17 (2) by amending paragraph (4) to read as fol18 lows:

19 ‘‘(4) The Director shall include with each Na20 tional Drug Control Strategy an evaluation of the ef21 fectiveness of Federal drug control during the pre22 ceding year. The evaluation shall include an assess23 ment of Federal drug control efforts, including—

24 ‘‘(A) assessment of the reduction of drug

25 use, including estimates of drug prevalence and
4

•HR 1926 EH1S

1 frequency of use as measured by national,

2 State, and local surveys of illicit drug use and

3 by other special studies of—

4 ‘‘(i) high-risk populations, including

5 school dropouts, the homeless and tran6 sient, arrestees, parolees, and probationers,

7 and juvenile delinquents; and

8 ‘‘(ii) drug use in the workplace and

9 the productivity lost by such use;

10 ‘‘(B) assessment of the reduction of drug

11 availability, as measured by—

12 ‘‘(i) the quantities of cocaine, heroin,

13 and marijuana available for consumption

14 in the United States;

15 ‘‘(ii) the amount of cocaine and heroin

16 entering the United States;

17 ‘‘(iii) the number of hectares of poppy

18 and coca cultivated and destroyed;

19 ‘‘(iv) the number of metric tons of

20 heroin and cocaine seized;

21 ‘‘(v) the number of cocaine processing

22 labs destroyed;

23 ‘‘(vi) changes in the price and purity

24 of heroin and cocaine;
5

•HR 1926 EH1S

1 ‘‘(vii) the amount and type of con2 trolled substances diverted from legitimate

3 retail and wholesale sources; and

4 ‘‘(viii) the effectiveness of Federal

5 technology programs at improving drug de6 tection capabilities at United States ports

7 of entry;

8 ‘‘(C) assessment of the reduction of the

9 consequences of drug use and availability, which

10 shall include estimation of—

11 ‘‘(i) burdens drug users placed on

12 hospital emergency rooms in the United

13 States, such as the quantity of drug-relat14 ed services provided;

15 ‘‘(ii) the annual national health care

16 costs of drug use, including costs associ17 ated with people becoming infected with

18 the human immunodeficiency virus and

19 other communicable diseases as a result of

20 drug use;

21 ‘‘(iii) the extent of drug-related crime

22 and criminal activity; and

23 ‘‘(iv) the contribution of drugs to the

24 underground economy, as measured by the
6

•HR 1926 EH1S

1 retail value of drugs sold in the United

2 States; and

3 ‘‘(D) determination of the status of drug

4 treatment in the United States, by assessing—

5 ‘‘(i) public and private treatment ca6 pacity within each State, including infor7 mation on the number of treatment slots

8 available in relation to the number actually

9 used, including data on intravenous drug

10 users and pregnant women;

11 ‘‘(ii) the extent, within each State, to

12 which treatment is available, on demand,

13 to intravenous drug users and pregnant

14 women;

15 ‘‘(iii) the number of drug users the

16 Director estimates could benefit from

17 treatment; and

18 ‘‘(iv) the success of drug treatment

19 programs, including an assessment of the

20 effectiveness of the mechanisms in place

21 federally, and within each State, to deter22 mine the relative quality of substance

23 abuse treatment programs, the qualifica24 tions of treatment personnel, and the

25 mechanism by which patients are admitted
7

•HR 1926 EH1S

1 to the most appropriate and cost effective

2 treatment setting.

3 ‘‘(5) The Director shall include with the Na4 tional Drug Control Strategy required to be submit5 ted not later than February 1, 1994, and with every

6 second such strategy submitted thereafter—

7 ‘‘(A) an assessment of the quality of cur8 rent drug use measurement instruments and

9 techniques to measure supply reduction and de10 mand reduction activities;

11 ‘‘(B) an assessment of the adequacy of the

12 coverage of existing national drug use measure13 ment instruments and techniques to measure

14 the casual drug user population and groups at15 risk for drug use;

16 ‘‘(C) an assessment of the actions the Di17 rector shall take to correct any deficiencies and

18 limitations identified pursuant to subpara19 graphs (A) and (B); and

20 ‘‘(D) identification of the specific factors

21 that restrict the availability of treatment serv22 ices to those seeking it and proposed adminis23 trative or legislative remedies to make treat24 ment available to those individuals.
8

•HR 1926 EH1S

1 ‘‘(6) Federal agencies responsible for the collec2 tion or estimation of drug-related information re3 quired by the Director shall cooperate with the Di4 rector, to the fullest extent possible, to enable the

5 Director to satisfy the requirements of sections 4

6 and 5.

7 ‘‘(7) By June 1, 1994, and with each National

8 Drug Control Strategy submitted thereafter, the Di9 rector shall report to the President and the Congress

10 on the Director’s assessment of drug use and avail11 ability in the United States, including an estimate of

12 the effectiveness of interdiction, treatment, preven13 tion, law enforcement, and international programs

14 under the National Drug Control Strategy in effect

15 in the preceding year in reducing drug use and

16 availability.’’.

17 SEC. 5. DIRECTOR AS A MEMBER OF THE NATIONAL SECU18 RITY COUNCIL.

19 Section 402(a)(7) of title 50, United States Code, is

20 amended by—

21 (1) striking ‘‘and’’ after the semicolon in para22 graph (6);

23 (2) redesignating paragraph (7) as paragraph

24 (8); and

25 (3) inserting after paragraph (6) the following:
9

•HR 1926 EH1S

1 ‘‘(7) the Director of the Office of National

2 Drug Control Policy; and’’.

3 SEC. 6. COUNTER-DRUG TECHNOLOGY ASSESSMENT CEN4 TER.

5 (a) DRUG ABUSE ADDICTION AND REHABILITATION

6 CENTER.—Section 1003A of the National Narcotics Lead7 ership Act of 1988 (21 U.S.C. 1502a(c)(1)) is amended—

8 (1) by redesignating subparagraphs (B), (C),

9 and (D) as subparagraphs (C), (D), and (E), respec10 tively; and

11 (2) by inserting after subparagraph (A) the fol12 lowing:

13 ‘‘(B) identify and support, through inter14 agency agreements or grants that are subjected

15 to peer review by independent advisory boards,

16 the application of technology to expanding the

17 effectiveness or availability of drug treatment;’’.

18 (b) ASSISTANCE FROM THE ADVANCED RESEARCH

19 PROJECT AGENCY.—Section 1003A of the National Nar20 cotics Leadership Act of 1988 (21 U.S.C. 1502a) is

21 amended by adding at the end the following:

22 ‘‘(f) ASSISTANCE AND SUPPORT TO OFFICE OF NA23 TIONAL DRUG CONTROL POLICY.—The Director of the

24 Advanced Research Project Agency shall, to the fullest ex-
10

•HR 1926 EH1S

1 tent possible, render assistance and support to the Office

2 of National Drug Control Policy and its Director.’’.

3 (c) REPEAL AND REDESIGNATION.—The National

4 Narcotics Leadership Act of 1988 is amended by—

5 (1) repealing section 1008 (21 U.S.C. 1505), as

6 in effect on the date of the enactment of this Act;

7 (2) redesignating section 1003A, as amended by

8 subsection (b) of this section, as section 1008; and

9 (3) moving such section, as redesignated, so as

10 to follow section 1007.

11 SEC. 7. PAYING CERTAIN NECESSARY EXPENSES FOR

12 STRATEGY CONSULTATION.

13 Section 1005(a)(3) of the National Narcotics Leader14 ship Act of 1988 (21 U.S.C. 1504(a)(3)) is amended by

15 adding at the end the following:

16 ‘‘(C) The Director may pay for the necessary and ap17 propriate expenses for assemblages of individuals provid18 ing consultation to the Director in developing the National

19 Drug Control Strategy.’’.

20 SEC. 8. AUTHORIZATION OF APPROPRIATIONS.

21 Section 1011 of the National Narcotics Leadership

22 Act of 1988 (21 U.S.C. 1508) is amended by striking

23 ‘‘$3,500,000’’ and all that follows through ‘‘years,’’ and

24 inserting ‘‘such sums as may be necessary for fiscal year

25 1994,’’.
11

•HR 1926 EH1S

1 SEC. 9. TERMINATION OF OFFICE OF NATIONAL DRUG CON2 TROL POLICY.

3 Section 1009 of the National Narcotics Leadership

4 Act of 1988 (21 U.S.C. 1506) is amended by striking ‘‘the

5 date which is 5 years after the date of the enactment of

6 this subtitle’’ and inserting ‘‘September 30, 1994’’.

Passed the House of Representatives November 21,

1993.

Attest:

Clerk.